Difficulties in the production and distribution of vaccines continue to hamper India's efforts to vaccinate its entire adult population by the end of this year. To date, the total number of those ful…
Covaxin
Taking cue from Serum Insistute of India, Hyderbad-based Bharat Biotech on Thursday reduced price of its coronavirus vaccine, Covaxin, for states to Rs 400 per dose from Rs 600.
This follows a widespread criticism of its pricing policy as it sold Covaxin to the central government at Rs 150 per dose. Recognising the enormous challenges in the public healthcare system, we have made Covaxin available to state governments at a price of 400/ dose , Bharat Biotech said in its announcement. The company is deeply concerned with the critical pandemic circumstances that India is facing at this time, it added. Serum Institute of India (SII) the maker of the most used COVID-19 vaccine in the country on Wednesday announced a cut in price of the jab it plans to sell to states to Rs 300 per dose from the earlier Rs 400.
Last Updated: India s COVID-19 Vaccines Will Benefit All Countries , Says Bhutan Ambassador To India
Bhutan s Ambassador to India spoke to 64 foreign envoys on board a plane to Delhi & said that India s COVID-19 vaccines will benefit most countries.
Following the 64 diplomat s tour of Hyderbad-based Bharat Biotech and Biological E, Bhutan s Ambassador to India spoke to the foreign envoys on board the plane back to New Delhi and said that India s COVID-19 vaccines will benefit most countries. Vetsop Namgyel stated that India s vaccines will be the easiest to administer and transport as the country is known to produce in bulk quantities . The 64 foreign envoys on the COVID-19 vaccines facilities tour were also briefed by Bharat Biotech s Chairman and Managing Director Dr Krishna Ella with regards to India s vaccine manufacturing capabilities.